Weitere Suchergebnisse zu "B.R.A.I.N. Biotechnology Research And Information Network":
 Aktien      Zertifikate    


DJ DGAP-Adhoc: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG sets IPO price at 9 Euros per share




03.02.16 18:40
Dow Jones Newswires



DJ DGAP-Adhoc: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG sets IPO price at 9 Euros per share





DGAP-Ad-hoc: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): IPO
B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG sets IPO price at 9 Euros per share

2016-02-03 / 18:40
Dissemination of an Ad hoc announcement according to § 15 WpHG.
The issuer is solely responsible for the content of this announcement.

The information contained herein is not for publication, release or distribution (directly or indirectly) in or into or
to persons in the United States of America, Canada, Japan and Australia or any other jurisdiction in which publication,
release or distribution would be unlawful.

AD HOC RELEASE

BRAIN AG sets IPO price at 9 Euros per share

Zwingenberg, February 3, 2016: B.R.A.I.N. Biotechnology Research and Information Network AG ("BRAIN AG") and ODDO
SEYDLER BANK AG ("ODDO SEYDLER") as sole global coordinator of the transaction have set the final offer price for BRAIN
shares at EUR 9 per share. The initial public offering ("IPO") is thus accomplished as planned.

A total of 3,608,054 shares were placed in the context of the offering. Thereof 3,500,000 shares result from a capital
increase. In addition, 108,054 existing shares were placed to cover over-allotments. This number of shares, provided by
way of a share loan, can be bought back by ODDO SEYDLER until the end of the stabilisation period (up to thirty calendar
days after the first day of trading) for market stabilisation reasons ("Greenshoe Option").

Based on the final offer price of 9 Euros, the total placement volume (including over-allotments) amounts to
approximately 32.5 million Euros, from which the Company will receive gross proceeds of 31.5 million Euros.

Following the IPO capital increase, the share capital of BRAIN AG will amount to 16,414,348 shares. The percentage of
the new shareholders in the Company's share capital will at least be 21.3% and, depending on if or to which extent the
Greenshoe Option is exercised, higher.

Approximately 19 per cent of the placed shares were allocated to retail investors. These are - amongst others - BRAIN
employees and investors of MIG funds, which are existing shareholders of BRAIN. The remaining shares were placed with
institutional investors from different European countries.

MP Beteiligungs-GmbH remains the largest single shareholder of BRAIN AG with reduced holdings from 50.65 per cent
pre-IPO to under 50 per cent post-IPO, even without exercise of the Greenshoe Option.

Admission of the BRAIN AG shares to the Frankfurt Stock Exchange is planned to take place on 5 February 2016; the
trading on the regulated market (Prime Standard segment) under the ticker symbol BNN and the ISIN DE0005203947 / WKN
520394 is expected to start on 9 February 2016.

+++ENDS+++

About BRAIN

BRAIN is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of
Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural
substances from complex biological systems that can be put to industrial use. The innovative solutions and products
developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food
industries. Today, BRAIN's business model is based on two pillars - "BioScience" and "BioIndustrial". The first pillar,
"BioScience", comprises its - frequently exclusive - collaboration business with industrial partners. The second pillar
"BioIndustrial" comprises the development and commercialisation of BRAIN's own products and active product components.
Further information is available at www.brain-biotech.de/en

B.R.A.I.N.
Biotechnology Research
And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany

Tel.: +49-6251-9331-0
Fax: +49-6251-9331-11
E-Mail: ir@brain-biotech.de
www.brain-biotech.de

Disclaimer

This document and the information contained herein are for information purposes only. This press release does not
constitute an offer to sell, or the solicitation of an offer to buy or subscribe for securities. A public offer in the
Federal Republic of Germany and in the Republic of Austria was made exclusively by means of and on the basis of an
English-language prospectus together with a German-language translation of the summary. The prospectus was published on
the website of the Company and is also available in printed form free of charge from the Company (Fax +49-6251-9331-11)
and from ODDO SEYDLER BANK AG (Fax +49-69-920-54902).

This press release does not constitute an offer to sell, or the solicitation of an offer to buy or subscribe for
securities in or into the United States of America, Australia, Canada or Japan or to other jurisdictions in which
publication, release or distribution would be unlawful. Any securities referred to herein have not been, and will not
be, registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act"). Such securities may not be
offered, sold or delivered within the United States absent from registration under or an applicable exemption from the
registration requirements of the U.S. Securities Act. Neither BRAIN AG nor any of its shareholders intends to register
the securities referred to in this press release in the United States. The securities referred to in this press release
have not been, and will not be, registered under the applicable securities laws of Australia, Canada or Japan. Subject
to certain exceptions, the securities may not be offered or sold in Australia, Canada or Japan or to, or for the account
or benefit of, any national, resident or citizen of Australia, Canada or Japan. There will be no public offering of
securities in the United States or anywhere outside of the Federal Republic of Germany and the Republic of Austria.

This press release does not constitute an offer document or an offer of transferable securities to the public in the
United Kingdom to which Section 85 of the U.K. Financial Services and Markets Act 2000 applies and should not be
considered as a recommendation that any person should subscribe for or purchase any securities as part of the
transaction. This press release is only being distributed to and is only directed at (i) persons who are outside the
United Kingdom or (ii) to investment professionals falling within Section 19 (5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (iii) high net worth entities, unincorporated
associations and other persons or entities falling within Section 49 (2), (a) to (d) of the Order (all such persons
together being referred to as "relevant persons"). This press release or its contents must not be acted or relied on by
persons who are not relevant persons. Any investment or investment activity to which this press release relates is
available only to relevant persons and will be engaged in only with relevant persons. This release (or parts thereof)
may not be published, reproduced, distributed or made available to third parties in any other way without the prior
consent of BRAIN AG.

This press release contains forward-looking statements. These statements reflect the current views, expectations, and
assumptions of the management of BRAIN AG and are based on information currently available to the management.
Forward-looking statements are not guarantees of future performance and involve known and unknown risks and
uncertainties that could cause actual results, performance or events to differ materially from those expressed or
implied in such statements. There are numerous factors which could influence the future performance by and future
developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the
general economic and competitive environment, risks associated with capital markets, currency exchange rate
fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and
regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking
statements.

2016-02-03 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press
Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: ir@brain-biotech.de
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard)
Notierung vorgesehen / intended to be listed (Frankfurt, Prime Standard)

End of News DGAP News Service
434553 2016-02-03




(END) Dow Jones Newswires




February 03, 2016 12:40 ET (17:40 GMT)









 
 
hier klicken zur Chartansicht

Aktuelle Kursinformationen mehr >
Kurs Vortag Veränderung Datum/Zeit
20,15 € 20,465 € -0,315 € -1,54% 17.11./20:30
 
ISIN WKN Jahreshoch Jahrestief
DE0005203947 520394 26,50 € 14,13 €
Handelsplatz Letzter Veränderung  Zeit
 
Tradegate (RT)
19,91 € -4,92%  17.11.17
Berlin 20,44 € +2,28%  17.11.17
Stuttgart 20,455 € -0,25%  17.11.17
München 20,04 € -0,40%  17.11.17
Düsseldorf 20,18 € -0,42%  17.11.17
Frankfurt 20,40 € -0,43%  17.11.17
Xetra 20,15 € -1,54%  17.11.17
  = Realtime
Aktien des Tages
  


Mit der Anmeldung für den Newsletter "Aktien des Tages" stimme ich dem gleichzeitigen Erhalt des "GeVestor täglich" unseres Partners GeVestor zu.


Mit der Anmeldung für den Newsletter "Aktien des Tages" stimme ich dem gleichzeitigen Erhalt des "Investors Daily" unseres Partners FID Verlag zu.

Meistgelesene Artikel
Aktuelle Diskussionen
Antw. Thema Zeit
250 B.R.A.I.N. Biotech. Research A. 11.11.17
RSS Feeds




Bitte warten...